Lmcg Investments LLC Purchases 65 Shares of Amgen Inc. (NASDAQ:AMGN)

Lmcg Investments LLC boosted its holdings in shares of Amgen Inc. (NASDAQ:AMGN) by 0.2% during the second quarter, Holdings Channel reports. The institutional investor owned 36,989 shares of the medical research company’s stock after acquiring an additional 65 shares during the quarter. Lmcg Investments LLC’s holdings in Amgen were worth $11,557,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Aveo Capital Partners LLC boosted its holdings in Amgen by 19.9% during the fourth quarter. Aveo Capital Partners LLC now owns 2,729 shares of the medical research company’s stock valued at $786,000 after purchasing an additional 453 shares in the last quarter. Gryphon Financial Partners LLC boosted its stake in Amgen by 295.3% in the 4th quarter. Gryphon Financial Partners LLC now owns 3,684 shares of the medical research company’s stock valued at $1,021,000 after buying an additional 2,752 shares in the last quarter. Level Four Advisory Services LLC grew its position in Amgen by 2.6% in the fourth quarter. Level Four Advisory Services LLC now owns 3,958 shares of the medical research company’s stock valued at $1,140,000 after acquiring an additional 100 shares during the period. Hillsdale Investment Management Inc. raised its stake in Amgen by 49.2% during the fourth quarter. Hillsdale Investment Management Inc. now owns 970 shares of the medical research company’s stock worth $279,000 after acquiring an additional 320 shares in the last quarter. Finally, Gladstone Institutional Advisory LLC raised its stake in Amgen by 5.7% during the fourth quarter. Gladstone Institutional Advisory LLC now owns 8,300 shares of the medical research company’s stock worth $2,390,000 after acquiring an additional 449 shares in the last quarter. Institutional investors own 76.50% of the company’s stock.

Amgen Trading Up 0.8 %

AMGN opened at $335.26 on Tuesday. The firm has a 50 day simple moving average of $328.66 and a 200 day simple moving average of $304.44. Amgen Inc. has a fifty-two week low of $249.70 and a fifty-two week high of $346.85. The company has a market cap of $179.85 billion, a price-to-earnings ratio of 47.89, a price-to-earnings-growth ratio of 2.93 and a beta of 0.61. The company has a debt-to-equity ratio of 9.64, a current ratio of 1.26 and a quick ratio of 0.89.

Amgen (NASDAQ:AMGN) last issued its earnings results on Tuesday, August 6th. The medical research company reported $4.97 EPS for the quarter, missing the consensus estimate of $5.01 by ($0.04). The business had revenue of $8.39 billion for the quarter, compared to the consensus estimate of $8.35 billion. Amgen had a net margin of 10.12% and a return on equity of 161.72%. The business’s revenue was up 20.1% on a year-over-year basis. During the same quarter in the previous year, the firm posted $5.00 EPS. On average, sell-side analysts anticipate that Amgen Inc. will post 19.49 earnings per share for the current year.

Amgen Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Tuesday, August 6th. Shareholders of record on Friday, August 16th were issued a dividend of $2.25 per share. This represents a $9.00 dividend on an annualized basis and a yield of 2.68%. The ex-dividend date of this dividend was Friday, August 16th. Amgen’s dividend payout ratio (DPR) is currently 128.57%.

Analyst Ratings Changes

AMGN has been the topic of several analyst reports. TD Cowen upped their target price on shares of Amgen from $360.00 to $381.00 and gave the stock a “buy” rating in a report on Wednesday, August 7th. Jefferies Financial Group reaffirmed a “buy” rating and set a $380.00 price objective (up from $375.00) on shares of Amgen in a research note on Wednesday, August 7th. Royal Bank of Canada lifted their target price on shares of Amgen from $332.00 to $362.00 and gave the company an “outperform” rating in a research note on Wednesday, August 7th. Wells Fargo & Company lowered Amgen from an “overweight” rating to an “equal weight” rating and increased their price target for the stock from $320.00 to $335.00 in a research report on Wednesday, August 7th. Finally, Morgan Stanley dropped their price target on Amgen from $310.00 to $303.00 and set an “equal weight” rating for the company in a report on Thursday, July 11th. Eleven investment analysts have rated the stock with a hold rating and eleven have issued a buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $327.28.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.